Insider Selling: TransMedics Group (NASDAQ:TMDX) Director Sells 5,000 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director David Weill sold 5,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the sale, the director directly owned 12,134 shares in the company, valued at approximately $1,682,257.76. The trade was a 29.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

TransMedics Group Price Performance

Shares of TMDX traded down $2.12 during trading hours on Friday, reaching $136.51. The stock had a trading volume of 462,535 shares, compared to its average volume of 1,213,045. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $156.00. The stock has a market capitalization of $4.66 billion, a PE ratio of 55.27 and a beta of 2.06. The company’s 50-day moving average is $124.55 and its two-hundred day moving average is $122.75.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.TransMedics Group’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.12 EPS. Research analysts expect that TransMedics Group, Inc. will post 1 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Morgan Stanley raised their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a report on Tuesday. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research report on Thursday, October 30th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Stifel Nicolaus initiated coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 price objective on the stock. Finally, Piper Sandler decreased their price objective on TransMedics Group from $145.00 to $140.00 and set an “overweight” rating for the company in a report on Thursday, October 30th. Seven equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $133.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of TransMedics Group by 0.3% during the third quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock worth $404,549,000 after buying an additional 9,650 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in TransMedics Group by 244.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company’s stock valued at $209,448,000 after acquiring an additional 2,209,996 shares during the last quarter. Geode Capital Management LLC grew its holdings in TransMedics Group by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock worth $107,845,000 after acquiring an additional 11,241 shares during the period. Driehaus Capital Management LLC raised its position in shares of TransMedics Group by 2.4% in the 1st quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company’s stock worth $52,395,000 after acquiring an additional 17,913 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of TransMedics Group by 54.2% in the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock worth $71,291,000 after acquiring an additional 223,409 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.